BDSX Biodesix

Biodesix to Participate in Three Investor Conferences in November

Biodesix to Participate in Three Investor Conferences in November

LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences:

Craig-Hallum 15th Annual Alpha Select Conference

1x1 Meetings

Date: Tuesday, November 19, 2024

Location: New York, NY

Wolfe Research Healthcare Conference 2024

1x1 Meetings

Date: Wednesday, November 20, 2024

Location: New York, NY

Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum

Presentation and 1x1 Meetings

Presentation Date and Time: Thursday, November 21, 2024 at 1:00 PM ET

Location: New York, NY

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Biodesix

Biodesix is a leading diagnostic solutions company with five Medicare-covered tests available for patients with lung diseases. The blood-based Nodify Lung® Nodule Risk Assessment, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood-based IQLung™ test portfolio for lung cancer patients integrates the GeneStrat® targeted ddPCR™ test, the GeneStrat NGS® test, and the VeriStrat® test to support treatment decisions across all stages of lung cancer and expedite personalized treatment. In addition, Biodesix collaborates with the world’s leading biopharmaceutical companies to provide biomarker discovery, diagnostic test development, and clinical trial support services. For more information, visit .

Note: Biodesix, Nodify Lung, IQLung, GeneStrat, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT are trademarks or registered trademarks of Biodesix, Inc. ddPCR is a trademark of Bio-Rad Laboratories, Inc.

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
29/10/2024

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Unveils October Lung Health Events in Colorado with the Assoc...

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients LOUISVILLE, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced three Colorado-based events in October for healthcare professionals and community members to collaborate...

9h / 39m 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
KRNY Kearny Financia...
ASA ASA ... (+10)

InsiderInsights.com Daily Ratings Report: September 23, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

KRNY KEARNY FINANCIAL CORP.
ASA ASA
CULP CULP INC.
MUX MCEWEN MINING INC.
AROC ARCHROCK INC.
BCDA BIOCARDIA
AOUT AMERICAN OUTDOOR BRANDS
BDSX INC.
BUKS BIODESIX
BUTLER NATIONAL CORP
09/24/25 September 24, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces One-for-Twenty Reverse Stock Split

Biodesix Announces One-for-Twenty Reverse Stock Split LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nasdaq”) on a split-adjusted basis when the ...

September 11, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Bes...

Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025. Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference Date: Thursday, September 11, 2025Location: New York, NY1x1 meetings only About Biodesix ...

September 5, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence...

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix ...

August 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch